Experimental cancer combo trial ends early
NCT ID NCT06035744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called CLN-617, alone or with the immunotherapy Keytruda, in 23 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. However, the trial was terminated, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CLN-617 (a fusion protein combining IL-2, LAIR2, HSA, and IL-12) and pembrolizumab (Keytruda)
What this could lead to
If successful, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to standard therapy.
What could go wrong
This is a very early Phase 1 trial, now terminated, so results are limited. The approach is still experimental and may not prove safe or effective in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Orlando Health
Orlando, Florida, 32806, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Chicago
Chicago, Illinois, 60637, United States